RET and thyroid cancer: 11a (Selpercatinib, LOXO-292), developed by Loxo Oncology for the treatment of various solid tumors, including NSCLC and thyroid cancer, is a highly selective receptor tyrosine kinase rearranged during transfection (RET) inhibitor with IC50 values of 0.4 nM and 0.8nM for RET wild-type and mutant-type (V804M), respectively [200,201].